Amazon One Medical members can get Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo GLP-1 pills in a program that integrates primary-care services with the technology company’s pharmacy business. https://t.co/fXFQuZxtKX ...

RT insomniac (@insomniacxbt)hims is like the hood trade for pharmaretail product going against the legacy giantsi can align with that narrative ...

From Makers Of Weight-Loss Pills To Anti-Wrinkle Shots, Meet South Korea’s Lab-Grown Billionaires https://t.co/N2vzWM9TGWIllustration: Hidayat via Adobe Firefly https://t.co/YcWDHoVz5n ...

When I started at Regeneron, the space I worked in had a name that sounded much nicer than it actually was. It was called the Skybox, and it was not a corner office. It was a work trailer built on risers in the warehouse above the loading dock.And when trucks backed in, my desk would shake. You could feel the doors rolling up and the pallets moving beneath you. Rain, wind, snow, it didn't matter.The skybox was a building inside the building, sealed off from the outside world, except for the rumble of the fr ...

Eli Lilly’s late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. https://t.co/hXH82cdSkd ...

Alzheimer’s drugs that target the buildup of the amyloid protein on the brain don’t meaningfully help patients, a major review found, raising questions about medicines developed by the likes of Eli Lilly and Eisai https://t.co/Om1hCYCbjL ...

INSIGHT: $BIO is today's top trending coin amid news of Eli Lilly’s acquisition of startup Crossbridge Bio. https://t.co/oKgAG07kKh ...

Suntory Holdings is set to acquire Daiichi Sankyo Healthcare, the over-the-counter pharmaceuticals subsidiary of Daiichi Sankyo, the Nikkei newspaper reports https://t.co/NtPKs0FHlo ...

From Makers Of Weight-Loss Pills To Anti-Wrinkle Shots, Meet South Korea’s Lab-Grown Billionaires https://t.co/N2vzWM9TGWIllustration: Hidayat via Adobe Firefly https://t.co/GSOoDoeApN ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Aquestive Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on May 4, 2026 [1]. Group 1: Class Action Details - Investors who bought Aquestive securities between June 16, 2025, and January 8, 2026, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by visiting the provided link or contacting the firm directly [3][6]. - The lawsuit alleges that the defendants made false or misleading statements regarding the New Drug Application for Anaphylm and concealed significant human factors related to its sublingual film [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience [4]. - Rosen Law Firm has a strong history in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its performance in securities class action settlements, ranking highly in the industry since 2013 [4].